 |
14 Diseases |  |
33 Trials |
|
33 Trials |  |
2608 News |  |
| «12...1112131415161718192021...3132» |
- Mavenclad (cladribine) / EMD Serono
[VIRTUAL] Cladribine in a real world setting. The real patients (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2409;
23 patients switch from teriflunomide, 16 from dimethylfumarate, 14 from fingolimod, 22 from injectables, 1 from alemtuzumab... In the real world cladribine has proved to be effective, safe and very well tolerated.
- dimethyl fumarate / Generic mfg., teriflunomide / Generic mfg.
[VIRTUAL] Real-world discontinuation rate of teriflunomide and dimethyl fumarate in multiple sclerosis (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2407;
In the real world cladribine has proved to be effective, safe and very well tolerated. Our findings suggests that dimethyl fumarate has a lower risk of discontinuation because of treatment failure among both treatment-experienced and treatment-naive patients.
- teriflunomide / Generic mfg.
[VIRTUAL] Patient-reported outcomes to assess quality of life in teriflunomide-treated patients with relapsing-remitting multiple sclerosis: Results of Teri-REAL – a real-world study from Hungary (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2403;
The Teri-REAL findings suggest favourable real-world efficacy and safety outcomes with teriflunomide in a Hungarian RRMS population. The measurement of MSQoL-54 and BICAMS over 2 years in these patients offers a unique perspective to this study.
- Mavenclad (cladribine) / EMD Serono
[VIRTUAL] Relapse during the washout period predicts time to relapse after switching to cladribine (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2400;
Washout durations shorter than two months were associated with fewer washout relapses. Prospective studies are needed to assess if washout period reduction can modify relapse outcomes when switching to cladribine.
- glatiramer acetate / Generic mfg., dimethyl fumarate / Generic mfg., teriflunomide / Generic mfg.
[VIRTUAL] Effectiveness of relapsing multiple sclerosis patients switching to teriflunomide following disease progression in a real-world setting (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2398;
Following switch to teriflunomide, patients demonstrated numerical reductions in mean EDSS, and most demonstrated stability or improvement in ARR, MRI lesions, and use of ambulatory aids. Long-term assessment of this cohort may aid in understanding the impact of teriflunomide on clinical outcomes in disease progressing RMS patients.
- glatiramer acetate / Generic mfg., teriflunomide / Generic mfg.
[VIRTUAL] Teriflunomide improves quality of life in a Greek cohort of relapsing-remitting multiple sclerosis patients switched from injectables: Subgroup analysis of previously-treated patients in the AURELIO study (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2394;
PRO-related data from the AURELIO study suggest that oral teriflunomide was associated with increased treatment satisfaction versus injectable DMTs in this subgroup of patients from Greece. A more convenient route of administration as well as greater perceived efficacy and tolerability likely explain these findings.
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] MASTER-2 trial: cladribine tablets in patients with relapsing-remitting multiple sclerosis and active secondary progressive multiple sclerosis after suboptimal response to prior infusion/oral disease-modifying therapy (interim baseline results) (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2391;
P=N/A
MASTER-2 will report real-world data on the effects of CladT3.5 after a suboptimal response to oral/infusion DMT. Baseline analysis is ongoing and results from a data cut in July 2021 will be shown in the presentation.
- Vumerity (diroximel fumarate) / Biogen, Fumaderm (dimethyl fumarate) / Biogen
[VIRTUAL] Early data suggests diroximel fumarate has high rates of real-world adherence and persistence (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2390;
The finding that higher persistence is seen with newer DMTs vs older DMTs should be explored in future matched comparisons. These data support DRF as a well-tolerated fumarate.
- teriflunomide / Generic mfg.
[VIRTUAL] Fatigue, depression and health-related productivity in multiple sclerosis patients treated with teriflunomide for 2 years in the real-world study TeriCARE (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2389;
After 2 years of teriflunomide, fatigue and depression levels remained low, according to score ranging of MFIS-21 and BDI-II, and work productivity increased. Favourable results in fatigue and depression may also explain the improvement in work productivity (HRPQ-MS v2).
- glatiramer acetate / Generic mfg., dimethyl fumarate / Generic mfg.
[VIRTUAL] Therapeutic management of relapsing-remitting multiple sclerosis in France in the recent era (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2383;
Our results suggest that moderately effective first-line DMTs do not always allow an effective control of the disease. Therapeutic management is a key element of current MS care (when switch and to what).
- Comirnaty (tozinameran) / Pfizer, Fosun Pharma, BioNTech, Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Anti-Spike IgG after BNT162b2 vaccine in a group of multiple sclerosis patients from an exploratory case-control study in Italy (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2376;
In our study, most MS patients produce a serological response to BNT162b2 similar to non-MS controls; however, at-risk DMTs resulted in reduced anti-Spike levels and one ocrelizumab-treated patient did not respond. These observations should be better investigated and replicated in larger studies to support clinical decision in COVID-19 vaccine management.
- Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Effectiveness and safety of early high-efficacy vs. escalation therapy in relapsing-remitting multiple sclerosis in Argentina (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2367;
Our study shows that EHE therapies prevent disease progression, relapses and new MRI lesions and demonstrated no increased risk of specific adverse events when compared to ES therapy. This data should be considered when selecting a specific treatment for MS patients.
- Mavenclad (cladribine) / EMD Serono
[VIRTUAL] Real-world experience with cladribine in the MSBase Registry (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2365;
The most common switches to cladribine are from other high-efficacy DMTs such as Natalizumab or Fingolimod. The annualised relapse rate on treatment is 0.11, consistent with clinical trial data.
- teriflunomide / Generic mfg.
[VIRTUAL] NEDA3PLUS study: 48-week interim results on persistence, clinical and MRI outcomes in RRMS patients treated with teriflunomide in a real-world setting (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2364;
In this population, the high treatment persistence observed at Week 48 might indicate good tolerability and safety. Moreover, most patients were free of clinical and MRI activity indicating good efficacy of teriflunomide in the short-term.
- dimethyl fumarate / Generic mfg., teriflunomide / Generic mfg.
[VIRTUAL] Comparative analysis of dimethyl fumarate and teriflunomide in relapsing-remitting multiple sclerosis (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2359;
Objective: To compare the clinical outcomes in patients on DMF and TFL in a real-world setting, where both drugs are licensed as a first-line disease modifying therapy (DMT) for RRMS... Analysis of real-world data showed that in RRMS, DMF treatment was associated with more favorable clinical outcomes compared to TFL.
- teriflunomide / Generic mfg.
[VIRTUAL] The effect of different national treatment strategies on disability outcome in relapsing-remitting multiple sclerosis: a propensity score adjusted comparison between Denmark and Sweden (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2355;
We show for the first time that differences in treatment strategies of RRMS have an impact on disability outcomes at a national level. Escalation of treatment efficacy seemed inferior to using more efficacious DMT as initial treatment.
- Mayzent (siponimod) / Novartis
[VIRTUAL] Assessing the immune response to SARS-CoV-2 mRNA vaccines in patients with secondary progressive multiple sclerosis treated with siponimod (AMA-VACC clinical trial) (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2348;
Cohort 1 receives SARS-CoV-2 mRNA vaccination while continuing their current siponimod treatment, cohort 2 interrupts siponimod treatment for for the purpose of a full vaccination cycle and cohort 3 receives vaccination during continuous treatment with first-line DMTs (dimethylfumarate, glatirameracetate, interferons, teriflunomide) or no current treatment in clinical routine... This analysis will provide first data on the immune response after SARS-CoV-2 mRNA vaccination in patients with SPMS treated with siponimod and enable physicians to make an informed decision on the coordination of SARS-CoV-2 mRNA vaccination and SPMS treatment.
- dimethyl fumarate / Generic mfg., teriflunomide / Generic mfg.
[VIRTUAL] Immunoglobulin repertoire analysis in multiple sclerosis patients reveals distinct treatment effects after initiation of dimethyl fumarate or teriflunomide therapy (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2343;
Although we observed slight differences in repertoire diversity on a subset level, no profound effect on maturation processes was detectable; additional patients are currently analyzed. Our results -at least partially- explain the relatively mild side effects regarding infections and moderate impact on vaccinations of both treatments.
- dimethyl fumarate / Generic mfg.
[VIRTUAL] Assessing treatment response to oral drugs for multiple sclerosis in real world setting: a MAGNIMS study (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2335;
We retrospectively collected data of RRMS patients who started fingolimod (FNG), teriflunomide (TNF) or dimethyl fumarate (DMF) according to the following criteria: treatment-naive or switching from injectable DMTs; at least 1 year treatment duration; brain MRI scan collected at baseline and year 1; at least 3 years of clinical follow-up... We extend the results of previous studies, by demonstrating that early relapses and MRI activity in the first year of treatment are associated with an increased risk of short-term confirmed disability worsening and relapses in patients treated with oral DMTs.
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Risk of cancer with disease-modifying drugs in multiple sclerosis: a new-user cohort design in the French nationwide claims database (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2293;
Results suggest a trend of increased risk of cancer in patients with MS who initiated IS compared with IIM. Longer follow-up of this patient population is warranted.
- Ponvory (ponesimod) / J&J
[VIRTUAL] Effect of ponesimod compared with teriflunomide on treatment with concomitant corticosteroids for relapse in patients with relapsing forms of multiple sclerosis (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2272;
P3
Reference: Kappos L et al. JAMA Neurol .
- Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] COVID-19 (inactivated and mRNA) vaccine and humoral response in people with multiple sclerosis: Chilean cohort (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2252;
In our cohort, most of the treatments are likely to produce humoral response to the COVID-19 vaccine, especially alemtuzumab, cladribine and natalizumab, regardless the infusion/administration time. Further study needs to be done that includes more patients with antiCD20 and fingolimod but also it is important that the studies take into consideration the type of vaccine (T cell dependent response), B cell reconstitution and lymphocyte subpopulations for B and T cells.
- Mayzent (siponimod) / Novartis
[VIRTUAL] Safety and tolerability of conversion to siponimod with and without titration in patients with advancing forms of relapsing multiple sclerosis: interim results of the phase 3b EXCHANGE study (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2242;
P3
Immediate conversion from other DMTs to siponimod had an acceptable safety and tolerability profile, with no unexpected findings. There was no evidence of a meaningful reduction in heart rate when initiating siponimod in the overall group or in subgroups stratified by prior DMTs, including subjects transitioning from fingolimod to siponimod without dose titration.
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] A retrospective review of COVID spike protein antibody development following COVID-19 vaccination in MS patients on disease modifying drugs (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2235;
This study is limited in retrospective design, small un-balanced groups, and lack of longitudinal data. We cannot exclude the possibility of a more robust delayed humoral response.
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] IgG immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within MS PATHS (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2222;
Quantifying post-vaccination IgG response across DMTs is crucial to optimize MS management. Data from ongoing sample collection will be presented at the meeting.
- glatiramer acetate / Generic mfg., dimethyl fumarate / Generic mfg.
[VIRTUAL] Comparison of multiple disease modifying therapies in multiple sclerosis with marginal structural models (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2217;
In addition, we found a superior effect of natalizumab on reducing the rate of disability worsening and improving disability. This study demonstrates the capacity of ATE and ATT MSM to evaluate the effectiveness of multiple MS therapies simultaneously.
- vidofludimus (IMU-838) / Immunic
[VIRTUAL] Safety and tolerability of IMU-838, a next-generation DHODH inhibitor in EMPhASIS: a randomized, placebo-controlled phase 2 trial in relapsing multiple sclerosis (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2215;
P2
In separate phase 2 trials in MS, patients treated with IMU-838 discontinued treatment less frequently and had a lower rate of side-effects typical of DHODH inhibitors than those treated with teriflunomide. The higher selectivity and lower off-target inhibition of protein kinases of IMU-838 may explain the favorable safety and tolerability profile.
- Mavenclad (cladribine) / EMD Serono
[VIRTUAL] Disease-modifying therapy effect on COVID-19 vaccine response in multiple sclerosis patients: data from two New York State Multiple Sclerosis Consortium centers (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2200;
MS patients treated with B-cell depleting medications and S1P modulators have significantly lower seroconversion after COVID-19 vaccination when compared to DMT-naïve patients and other DMT groups. Future studies should determine the risk of severe clinical outcomes in vaccinated patients with no evidence of seroconversion.
- teriflunomide / Generic mfg.
[VIRTUAL] Oral teriflunomide effect on visual function in multiple sclerosis: multifocal electroretinogram responses after 12 months of treatment (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2191;
After 12 months of teriflunomide oral treatment in RRMS patients, we observed significant improvement in retinal function, revealed by increased wave amplitudes and decreased latencies. Considering lack of a control group, the small sample size and the variability of mfERG explorations, these results require further confirmation.
- Ponvory (ponesimod) / J&J
[VIRTUAL] Ponesimod shows improved effect on Brain Volume compared with other DMTs, a model-based meta-analysis (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2157;
Based on the MBMA results, ponesimod, the only monospecific S1P1 modulator, has shown improved brain volume data compared with other MS DMTs. Additional studies looking at direct CNS effects of ponesimod could help explain the beneficial effect on BVL.
- teriflunomide / Generic mfg.
[VIRTUAL] Plasma neurofilament light chain in children with relapsing MS receiving teriflunomide or placebo: A post hoc analysis of the randomised TERIKIDS trial (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2144;
P3
Additional studies looking at direct CNS effects of ponesimod could help explain the beneficial effect on BVL. This preliminary analysis suggests that teriflunomide treatment is associated with a decrease in pNfL levels in children with relapsing MS.
- teriflunomide / Generic mfg.
[VIRTUAL] Clustering is associated with poor response to teriflunomide in multiple sclerosis patients (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2139;
These findings support a role for CLU as a treatment response biomarker in RRMS receiving teriflunomide. Mechanistic studies are currently underway to investigate the functional implication of CLU in the response to teriflunomide.
- Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab
[VIRTUAL] Effect of ofatumumab on brain volume loss vs historical placebo in relapsing multiple sclerosis (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2095;
In the phase 3 ASCLEPIOS I/II trials, ofatumumab 20 mg administered subcutaneously every 4 weeks (q4w) was superior to oral teriflunomide 14 mg once daily, with significant reduction in relapse rates, lesion numbers on MRI, neurofilament light levels greater delays in disability worsening in patients with RMS...MRI scans for RMS patients treated with placebo were collected at baseline, month 6, year 1 2 in the FREEDOMS and FREEDOMS II trials, a Phase 3 trials involving fingolimod... Based on our analysis using identical MRI methodology causal inference methods, ofatumumab significantly reduced disease related BVL when compared with placebo.
- teriflunomide / Generic mfg.
[VIRTUAL] Impact of teriflunomide on innate immune cell activation in RRMS patients with limited signs of CNS pathology (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_2059;
P=N/A, P4
Innate immune cell activation was not altered during one year of teriflunomide treatment in any region of interest, and the patients remained clinically stable. However, due to the relatively mild nature of the cohort, and the initial low innate immune cell activation, the effect of teriflunomide on progression-promoting microglial activation remains unclear.
- glatiramer acetate / Generic mfg., dimethyl fumarate / Generic mfg.
[VIRTUAL] Evaluating DMT escalation based on isolated MRI activity (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_1992;
Methods : From the Vienna Innsbruck MS database (VIMSD), we included RMS patients (18-65 years) with a) newly initiated moderately effective DMT (interferon-beta, glatiramer acetate, dimethyl fumarate, or teriflunomide) continued for 12 months, b) clinical stability (no relapses or disability progression) on DMT for 12 months, c) MRI at baseline (MRI-0) and after 12 months of DMT (MRI-1), and d) available clinical follow-up for ≥3 years... In our real-world cohort of clinically stable patients, DMT escalation based on isolated MRI activity only changed outcome when MRI activity fulfilled at least MAGNIMS criteria (exceeding 3 new/enlarged T2 lesions).
- Ponvory (ponesimod) / J&J
[VIRTUAL] Ponesimod demonstrated increased clinical benefit over teriflunomide in early disease subgroup compared with overall population (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_1917;
Ponesimod demonstrated increased clinical benefit as compared with teriflunomide in early disease subgroups and compared with the overall population. This subgroup analysis confirms the advantage of using ponesimod as an early high efficacy treatment.
- Kesimpta (ofatumumab subcutaneous) / Novartis, Genmab, Mavenclad (cladribine) / EMD Serono
[VIRTUAL] Cost-effectiveness of ofatumumab in comparison with other disease modifying therapies and best supportive care for the treatment of relapsing-remitting multiple sclerosis in Canada (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_1871;
Considering first-line therapies, ofatumumab was dominant (more efficacy, lower costs) over teriflunomide, interferons, dimethyl fumarate, and ocrelizumab, and resulted in incremental cost-utility ratios (ICURs) of $24,177 Canadian dollars per quality-adjusted life-years (QALYs) gained versus glatiramer acetate and $28,034 versus BSC... In Canada, ofatumumab is cost effective against all comparators and dominant compared to all currently approved and reimbursed first-line DMTs for the treatment of patients with RRMS, except glatiramer acetate.
- glatiramer acetate / Generic mfg.
[VIRTUAL] Effect of disease-modifying treatments on cognitive impairment in MS (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_1861;
However, the comparison of results is limited by inhomogeneity between groups (more severe patients in the NTZ group) and the performance of tests at different times (older tests for the NTZ and IFN/AG groups). In conclusion, in our study NTZ was a more effective treatment alternative than FTY, TRF and IFN/AG in reducing cognitive impairment.
- teriflunomide / Generic mfg.
[VIRTUAL] Teriflunomide and cognition: a longitudinal study (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_1860;
Results suggest that TRF treatment in RRMS has a positive effect in cognitive functioning, and specifically on long term verbal memory, and, to a lesser extent, in inhibition. Neuroimaging correlates are currently being processed and will be presented during the meeting.
- Ponvory (ponesimod) / J&J
[VIRTUAL] Relationships between brain volume and disability, cognition, motor function, and MS-fatigue in RMS: MS-fatigue and ambulation move at their own pace (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_1852;
The OPTIMUM study compared ponesimod (20mg) to teriflunomide (14mg) over 108 weeks. There are statistically significant relationships between BV and clinical outcome measures of disability, cognition, motor function, and MS-fatigue; however, ambulation and MS-fatigue were not associated with the PBVC.
- Fumaderm (dimethyl fumarate) / Biogen
[VIRTUAL] Disease activity and patient-reported outcomes in patients with multiple sclerosis switching from first-line platform therapies to dimethyl fumarate (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_1847;
P=N/A
Overall, results suggest that DMF is an effective treatment option for patients with RRMS previously treated with injectable therapies or teriflunomide, regardless of the reasons that led to the switch from the previous first-line treatment. Supported by: Biogen
- Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] Real-world patient-reported outcomes in RRMS patients transitioning to alemtuzumab: results from the PRO-ACT study (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_1834;
Significant improvements in employment and household productivity were seen after switching, which may reflect a reduction in the burden that MS imposes on patients with employment and household responsibilities. Alemtuzumab safety was consistent with the pivotal studies.
- Mavenclad (cladribine) / EMD Serono, Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] COVID-19 in a neuroimmunology and multiple sclerosis referral unit (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_1804;
Los datos de nuestra serie estan en concordancia con otros estudios, mostrando que la esclerosis múltiple per se y los diferentes tratamientos immunomoduladors no son un factor de riesgo para el COVID19. Es importante acelerar la vacunación de los pacientes con esclerosis múltiple para reducir la posibilidad de infección por SARS-CoV-2.
- Mavenclad (cladribine) / EMD Serono
[VIRTUAL] Disease modifying therapy and pregnancy outcomes in multiple sclerosis: a systematic review and meta-analysis (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_1742;
Live birth with birth defects in Multiple Sclerosis patients treated with Natalizumab were statistically significant in comparison to Glatiramer Acetate. Whereas Live birth with birth defects in MS patients treated with Fingolimod, Dimethyl Fumarate, Teriflunomide and all Interferons were not significant compare to Glatiramer Acetate.
- teriflunomide / Generic mfg.
[VIRTUAL] Pregnancy-related outcomes in persons with MS exposed to teriflunomide (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_1741;
Whereas Live birth with birth defects in MS patients treated with Fingolimod, Dimethyl Fumarate, Teriflunomide and all Interferons were not significant compare to Glatiramer Acetate. Any adverse pregnancy outcomes reported to TFL-exposed males and females are accordant with those of the general population.
- Actemra IV (tocilizumab) / Roche, JW Pharma, Lemtrada (alemtuzumab) / Sanofi
[VIRTUAL] COVID-19 in patients with multiple sclerosis and neuromyelitis optica spectrum disorder in Colombia (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_1711;
No significant differences were observed by sex and treatment type in prognosis and mortality from COVID-19. However, we suggested to carry out robust sample studies to identify the main complicating factors and severity.
- glatiramer acetate / Generic mfg.
[VIRTUAL] Late onset multiple sclerosis Isfahan Iran (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_1708;
LOMS patients have high prevalence of comorbidities that differ from adult ms. Furthermore, the family history of MS is statistically significant in our study.
- glatiramer acetate / Generic mfg., dimethyl fumarate / Generic mfg.
[VIRTUAL] Is there a multiple sclerosis (MS) personality? Personality characteristics in persons with recently diagnosed MS at a single Canadian centre (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_1628;
Extraversion is less prominent. Females are significantly more likely to be Agreeable and Conscientious than males.
- teriflunomide / Generic mfg.
[VIRTUAL] Teriflunomide and Work problems in multiple sclerosis (ePoster Library) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_1626;
Females are significantly more likely to be Agreeable and Conscientious than males. PwMS on teriflunomide exhibit cognitive stability over two years, with employed patients demonstrating preserved work status.
- dimethyl fumarate / Generic mfg., teriflunomide / Generic mfg.
[VIRTUAL] Comparative analysis of dimethyl fumarate and teriflunomide in relapsing-remitting multiple sclerosis (Stream 7 Therapy / Global views) - Sep 23, 2021 - Abstract #ECTRIMS2021ECTRIMS_1539;
Objective: To compare the clinical outcomes in patients on DMF and TFL in a real-world setting, where both drugs are licensed as a first-line disease modifying therapy (DMT) for RRMS... Analysis of real-world data showed that in RRMS, DMF treatment was associated with more favorable clinical outcomes compared to TFL.